| samatasvir (IDX719) / Merck (MSD) |
NCT01335607: A Open-label Study to Evaluate the Relative Bioavailability of Samatasvir (IDX184) and Food Effect in Healthy Male Participants (MK-2355-006) |
|
|
| Completed | 1 | 12 | US | Samatasvir tablet, Samatasvir capsule | Merck Sharp & Dohme LLC | Hepatitis C | 05/11 | 05/11 | | |
NCT01813552: To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006) |
|
|
| Completed | 1 | 24 | US | Samatasvir, Omeprazole, Ritonavir | Merck Sharp & Dohme LLC | Chronic Hepatitis C Infection | 03/13 | 03/13 | | |
NCT01813513: Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004) |
|
|
| Completed | 1 | 42 | US | IDX719, Samatasvir, Simeprevir, Olysio™ | Merck Sharp & Dohme LLC | Chronic Hepatitis C Infection | 07/13 | 07/13 | | |
NCT01907724: Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007) |
|
|
| Completed | 1 | 34 | US | IDX719, Simeprevir, Olysio™, TMC647055, RTV, Norvir™ | Merck Sharp & Dohme LLC, Janssen Research & Development, LLC | Hepatitis C, Chronic | 08/13 | 08/13 | | |
NCT01919125: Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008) |
|
|
| Completed | 1 | 36 | US | IDX719, Samatasvir | Merck Sharp & Dohme LLC | Hepatitis C, Chronic | 02/14 | 02/14 | | |
